Nucleix
Daniel Neiman has worked as a Senior Research Scientist at Nucleix Ltd. since 2022 and as a Postdoctoral Researcher at The Hebrew University of Jerusalem since 2017.
Daniel Neiman has a diverse educational background. Daniel began their studies in 2006, earning a Bachelor of Science (B.Sc.) in Biotechnology from Hadassa College. Daniel then went on to obtain a Master of Science (M.Sc.) in Imprinting Establishment from The Hebrew University in 2009. In 2011, they completed their Doctor of Philosophy (PhD) in Epigenetic from The Hebrew University of Jerusalem. Finally, in 2017, they obtained a Post Doc in Biochemistry and Molecular Biology from The Hebrew University of Jerusalem.
This person is not in any offices
Nucleix
Nucleix is a global leader in creating cancer diagnostic panels based on epigenetic biomarkers. Backed by OrbiMed and other leading investors, Nucleix provides a strong pipeline of products for various cancer types.